HUIZHONG NEWS

What’s going on? A wave of pig farmers has suddenly become very happy—surprisingly, for this very reason…

Recently, the editor noticed that many pig farmers were extremely pleased, which left them puzzled—why was that? It wasn’t until the editor learned some major news: on November 6, 2018, a highly anticipated launch event was held in Luoyang for a bivalent inactivated vaccine against porcine circovirus type 2 and Mycoplasma hyopneumoniae, developed over eight years. According to reports, this bivalent inactivated vaccine was meticulously created by Luoyang Huizhong Biotechnology Co., Ltd., leveraging the expertise of the National Engineering Research Center for Veterinary Drugs. It effectively addresses two major challenges faced by pig farmers, enabling them to better manage disease prevention and control in their herds.

2018-11-10

China’s water‑based adjuvant bivalent inactivated vaccine against Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae has been officially launched.

On November 6, 2018, a grand launch event was held in Luoyang for the water-adjuvanted bivalent inactivated vaccine against Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae, which took eight years to develop. This vaccine was meticulously researched and developed by Luoyang Huizhong Biotechnology Co., Ltd., leveraging the expertise of the National Engineering Research Center for Veterinary Drugs. Luoyang Huizhong Biotechnology Co., Ltd. is a wholly owned subsidiary of Placor Bioengineering Co., Ltd., a leading domestic innovator in animal health technology. Established in 2011, the company builds on the successful 20-year operation of Luoyang Huizhong Veterinary Medicine and the 10-year track record of Placor Bio.

2018-11-08

The Porcine Circovirus Type 2 Bivalent Vaccine is now available—providing dual protection with a single dose, making pig farming even more hassle-free!

On November 6, 2018, Luoyang Huizhong Biotechnology Co., Ltd. (a wholly owned subsidiary of Placor Bioengineering Co., Ltd.), held a product launch event in Luoyang for its bivalent inactivated vaccine against Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae, which was developed over eight years with the support of the National Engineering Research Center for Veterinary Drugs. The “Bivalent Inactivated Vaccine Against Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae” represents a major scientific and technological achievement attained by Huizhong Biotechnology Co., Ltd. through its commitment to the business philosophy of “upright and prudent management,” its strategic vision of “innovation shapes the future,” and the robust technical platform provided by the National Engineering Research Center for Veterinary Drugs. It possesses…

2018-11-08

< 1 >